Scientists have developed the world’s first drug, muvalaplin, to treat high levels of lipoprotein(a), a type of “bad cholesterol” linked to increased risk of heart attacks and strokes. The drug successfully lowered lipoprotein(a) levels by up to 65% in a phase I clinical trial, proving to be safe with minimal side effects. People of African and South Asian descent are most at risk for high levels of lipoprotein(a). The drug is considered a game-changer in treating this previously untreatable form of cholesterol. Phase II trials are underway to determine its effectiveness in reducing heart attacks caused by elevated lipoprotein(a) levels.
Source link
New Drug Drops Bad Cholesterol by 65%
